| Record Information |
|---|
| Version | 5.0 |
|---|
| Status | Expected but not Quantified |
|---|
| Creation Date | 2013-06-15 17:50:45 UTC |
|---|
| Update Date | 2021-09-14 15:45:55 UTC |
|---|
| HMDB ID | HMDB0060607 |
|---|
| Secondary Accession Numbers | |
|---|
| Metabolite Identification |
|---|
| Common Name | Fluoxetine glucuronide |
|---|
| Description | Fluoxetine glucuronide is a metabolite of fluoxetine. Fluoxetine (also known by the tradenames Prozac, Sarafem, Fontex, among others) is an antidepressant of the selective serotonin reuptake inhibitor (SSRI) class. Fluoxetine was first documented in 1974 by scientists from Eli Lilly and Company. It was presented to the U.S. Food and Drug Administration in February 1977, with Eli Lilly receiving final approval to market the drug in December 1987. Fluoxetine went off-patent in August 2001 (Wikipedia). |
|---|
| Structure | CN(CCC(OC1=CC=C(C=C1)C(F)(F)F)C1=CC=CC=C1)[C@@H]1O[C@@H]([C@@H](O)[C@H](O)[C@H]1O)C(O)=O InChI=1S/C23H26F3NO7/c1-27(21-19(30)17(28)18(29)20(34-21)22(31)32)12-11-16(13-5-3-2-4-6-13)33-15-9-7-14(8-10-15)23(24,25)26/h2-10,16-21,28-30H,11-12H2,1H3,(H,31,32)/t16?,17-,18-,19+,20-,21+/m0/s1 |
|---|
| Synonyms | | Value | Source |
|---|
| (2S,3S,4S,5R,6R)-3,4,5-Trihydroxy-6-[methyl({3-phenyl-3-[4-(trifluoromethyl)phenoxy]propyl})amino]oxane-2-carboxylate | HMDB |
|
|---|
| Chemical Formula | C23H26F3NO7 |
|---|
| Average Molecular Weight | 485.456 |
|---|
| Monoisotopic Molecular Weight | 485.16613667 |
|---|
| IUPAC Name | (2S,3S,4S,5R,6R)-3,4,5-trihydroxy-6-[methyl({3-phenyl-3-[4-(trifluoromethyl)phenoxy]propyl})amino]oxane-2-carboxylic acid |
|---|
| Traditional Name | (2S,3S,4S,5R,6R)-3,4,5-trihydroxy-6-[methyl({3-phenyl-3-[4-(trifluoromethyl)phenoxy]propyl})amino]oxane-2-carboxylic acid |
|---|
| CAS Registry Number | 96735-71-6 |
|---|
| SMILES | CN(CCC(OC1=CC=C(C=C1)C(F)(F)F)C1=CC=CC=C1)[C@@H]1O[C@@H]([C@@H](O)[C@H](O)[C@H]1O)C(O)=O |
|---|
| InChI Identifier | InChI=1S/C23H26F3NO7/c1-27(21-19(30)17(28)18(29)20(34-21)22(31)32)12-11-16(13-5-3-2-4-6-13)33-15-9-7-14(8-10-15)23(24,25)26/h2-10,16-21,28-30H,11-12H2,1H3,(H,31,32)/t16?,17-,18-,19+,20-,21+/m0/s1 |
|---|
| InChI Key | ROQAUFRWFXOLOE-FEKBJPIOSA-N |
|---|
| Chemical Taxonomy |
|---|
| Description | Belongs to the class of organic compounds known as n-glucuronides. These are glucuronides in which the aglycone is linked to the carbohydrate unit through a N-glycosidic bond. |
|---|
| Kingdom | Organic compounds |
|---|
| Super Class | Organic oxygen compounds |
|---|
| Class | Organooxygen compounds |
|---|
| Sub Class | Carbohydrates and carbohydrate conjugates |
|---|
| Direct Parent | N-glucuronides |
|---|
| Alternative Parents | |
|---|
| Substituents | - N-glucuronide
- 1-n-glucuronide
- Glycosyl compound
- N-glycosyl compound
- Trifluoromethylbenzene
- Phenoxy compound
- Phenol ether
- Alkyl aryl ether
- Beta-hydroxy acid
- Monocyclic benzene moiety
- Hydroxy acid
- Benzenoid
- Monosaccharide
- Pyran
- Oxane
- Hemiaminal
- Secondary alcohol
- Carboxylic acid derivative
- Carboxylic acid
- Ether
- Oxacycle
- Organoheterocyclic compound
- Monocarboxylic acid or derivatives
- Polyol
- Hydrocarbon derivative
- Alkyl fluoride
- Organohalogen compound
- Organofluoride
- Carbonyl group
- Organic oxide
- Alkyl halide
- Alcohol
- Amine
- Organic nitrogen compound
- Organopnictogen compound
- Organonitrogen compound
- Aromatic heteromonocyclic compound
|
|---|
| Molecular Framework | Aromatic heteromonocyclic compounds |
|---|
| External Descriptors | Not Available |
|---|
| Ontology |
|---|
| Physiological effect | Not Available |
|---|
| Disposition | |
|---|
| Process | |
|---|
| Role | Not Available |
|---|
| Physical Properties |
|---|
| State | Not Available |
|---|
| Experimental Molecular Properties | | Property | Value | Reference |
|---|
| Melting Point | Not Available | Not Available | | Boiling Point | Not Available | Not Available | | Water Solubility | Not Available | Not Available | | LogP | Not Available | Not Available |
|
|---|
| Experimental Chromatographic Properties | Not Available |
|---|
| Predicted Molecular Properties | |
|---|
| Predicted Chromatographic Properties | Predicted Collision Cross SectionsPredicted Retention Times Underivatized| Chromatographic Method | Retention Time | Reference |
|---|
| Measured using a Waters Acquity ultraperformance liquid chromatography (UPLC) ethylene-bridged hybrid (BEH) C18 column (100 mm × 2.1 mm; 1.7 μmparticle diameter). Predicted by Afia on May 17, 2022. Predicted by Afia on May 17, 2022. | 4.58 minutes | 32390414 | | Predicted by Siyang on May 30, 2022 | 14.8031 minutes | 33406817 | | Predicted by Siyang using ReTip algorithm on June 8, 2022 | 3.65 minutes | 32390414 | | Fem_Long = Waters ACQUITY UPLC HSS T3 C18 with Water:MeOH and 0.1% Formic Acid | 2653.4 seconds | 40023050 | | Fem_Lipids = Ascentis Express C18 with (60:40 water:ACN):(90:10 IPA:ACN) and 10mM NH4COOH + 0.1% Formic Acid | 252.1 seconds | 40023050 | | Life_Old = Waters ACQUITY UPLC BEH C18 with Water:(20:80 acetone:ACN) and 0.1% Formic Acid | 190.8 seconds | 40023050 | | Life_New = RP Waters ACQUITY UPLC HSS T3 C18 with Water:(30:70 MeOH:ACN) and 0.1% Formic Acid | 189.2 seconds | 40023050 | | RIKEN = Waters ACQUITY UPLC BEH C18 with Water:ACN and 0.1% Formic Acid | 183.1 seconds | 40023050 | | Eawag_XBridgeC18 = XBridge C18 3.5u 2.1x50 mm with Water:MeOH and 0.1% Formic Acid | 607.6 seconds | 40023050 | | BfG_NTS_RP1 =Agilent Zorbax Eclipse Plus C18 (2.1 mm x 150 mm, 3.5 um) with Water:ACN and 0.1% Formic Acid | 656.7 seconds | 40023050 | | HILIC_BDD_2 = Merck SeQuant ZIC-HILIC with ACN(0.1% formic acid):water(16 mM ammonium formate) | 75.5 seconds | 40023050 | | UniToyama_Atlantis = RP Waters Atlantis T3 (2.1 x 150 mm, 5 um) with ACN:Water and 0.1% Formic Acid | 1189.3 seconds | 40023050 | | BDD_C18 = Hypersil Gold 1.9µm C18 with Water:ACN and 0.1% Formic Acid | 579.4 seconds | 40023050 | | UFZ_Phenomenex = Kinetex Core-Shell C18 2.6 um, 3.0 x 100 mm, Phenomenex with Water:MeOH and 0.1% Formic Acid | 1655.2 seconds | 40023050 | | SNU_RIKEN_POS = Waters ACQUITY UPLC BEH C18 with Water:ACN and 0.1% Formic Acid | 354.1 seconds | 40023050 | | RPMMFDA = Waters ACQUITY UPLC BEH C18 with Water:ACN and 0.1% Formic Acid | 436.5 seconds | 40023050 | | MTBLS87 = Merck SeQuant ZIC-pHILIC column with ACN:Water and :ammonium carbonate | 255.2 seconds | 40023050 | | KI_GIAR_zic_HILIC_pH2_7 = Merck SeQuant ZIC-HILIC with ACN:Water and 0.1% FA | 87.2 seconds | 40023050 | | Meister zic-pHILIC pH9.3 = Merck SeQuant ZIC-pHILIC column with ACN:Water 5mM NH4Ac pH9.3 and 5mM ammonium acetate in water | 8.0 seconds | 40023050 |
Predicted Kovats Retention IndicesUnderivatizedDerivatized| Derivative Name / Structure | SMILES | Kovats RI Value | Column Type | Reference |
|---|
| Fluoxetine glucuronide,1TMS,isomer #1 | CN(CCC(OC1=CC=C(C(F)(F)F)C=C1)C1=CC=CC=C1)[C@@H]1O[C@H](C(=O)O)[C@@H](O[Si](C)(C)C)[C@H](O)[C@H]1O | 3037.3 | Semi standard non polar | 33892256 | | Fluoxetine glucuronide,1TMS,isomer #2 | CN(CCC(OC1=CC=C(C(F)(F)F)C=C1)C1=CC=CC=C1)[C@@H]1O[C@H](C(=O)O)[C@@H](O)[C@H](O[Si](C)(C)C)[C@H]1O | 3035.9 | Semi standard non polar | 33892256 | | Fluoxetine glucuronide,1TMS,isomer #3 | CN(CCC(OC1=CC=C(C(F)(F)F)C=C1)C1=CC=CC=C1)[C@@H]1O[C@H](C(=O)O)[C@@H](O)[C@H](O)[C@H]1O[Si](C)(C)C | 3064.1 | Semi standard non polar | 33892256 | | Fluoxetine glucuronide,1TMS,isomer #4 | CN(CCC(OC1=CC=C(C(F)(F)F)C=C1)C1=CC=CC=C1)[C@@H]1O[C@H](C(=O)O[Si](C)(C)C)[C@@H](O)[C@H](O)[C@H]1O | 3021.7 | Semi standard non polar | 33892256 | | Fluoxetine glucuronide,2TMS,isomer #1 | CN(CCC(OC1=CC=C(C(F)(F)F)C=C1)C1=CC=CC=C1)[C@@H]1O[C@H](C(=O)O[Si](C)(C)C)[C@@H](O[Si](C)(C)C)[C@H](O)[C@H]1O | 3061.9 | Semi standard non polar | 33892256 | | Fluoxetine glucuronide,2TMS,isomer #2 | CN(CCC(OC1=CC=C(C(F)(F)F)C=C1)C1=CC=CC=C1)[C@@H]1O[C@H](C(=O)O)[C@@H](O[Si](C)(C)C)[C@H](O[Si](C)(C)C)[C@H]1O | 3067.1 | Semi standard non polar | 33892256 | | Fluoxetine glucuronide,2TMS,isomer #3 | CN(CCC(OC1=CC=C(C(F)(F)F)C=C1)C1=CC=CC=C1)[C@@H]1O[C@H](C(=O)O)[C@@H](O[Si](C)(C)C)[C@H](O)[C@H]1O[Si](C)(C)C | 3083.8 | Semi standard non polar | 33892256 | | Fluoxetine glucuronide,2TMS,isomer #4 | CN(CCC(OC1=CC=C(C(F)(F)F)C=C1)C1=CC=CC=C1)[C@@H]1O[C@H](C(=O)O[Si](C)(C)C)[C@@H](O)[C@H](O[Si](C)(C)C)[C@H]1O | 3056.8 | Semi standard non polar | 33892256 | | Fluoxetine glucuronide,2TMS,isomer #5 | CN(CCC(OC1=CC=C(C(F)(F)F)C=C1)C1=CC=CC=C1)[C@@H]1O[C@H](C(=O)O)[C@@H](O)[C@H](O[Si](C)(C)C)[C@H]1O[Si](C)(C)C | 3076.5 | Semi standard non polar | 33892256 | | Fluoxetine glucuronide,2TMS,isomer #6 | CN(CCC(OC1=CC=C(C(F)(F)F)C=C1)C1=CC=CC=C1)[C@@H]1O[C@H](C(=O)O[Si](C)(C)C)[C@@H](O)[C@H](O)[C@H]1O[Si](C)(C)C | 3070.5 | Semi standard non polar | 33892256 | | Fluoxetine glucuronide,3TMS,isomer #1 | CN(CCC(OC1=CC=C(C(F)(F)F)C=C1)C1=CC=CC=C1)[C@@H]1O[C@H](C(=O)O[Si](C)(C)C)[C@@H](O[Si](C)(C)C)[C@H](O[Si](C)(C)C)[C@H]1O | 3092.8 | Semi standard non polar | 33892256 | | Fluoxetine glucuronide,3TMS,isomer #2 | CN(CCC(OC1=CC=C(C(F)(F)F)C=C1)C1=CC=CC=C1)[C@@H]1O[C@H](C(=O)O[Si](C)(C)C)[C@@H](O[Si](C)(C)C)[C@H](O)[C@H]1O[Si](C)(C)C | 3109.4 | Semi standard non polar | 33892256 | | Fluoxetine glucuronide,3TMS,isomer #3 | CN(CCC(OC1=CC=C(C(F)(F)F)C=C1)C1=CC=CC=C1)[C@@H]1O[C@H](C(=O)O)[C@@H](O[Si](C)(C)C)[C@H](O[Si](C)(C)C)[C@H]1O[Si](C)(C)C | 3122.5 | Semi standard non polar | 33892256 | | Fluoxetine glucuronide,3TMS,isomer #4 | CN(CCC(OC1=CC=C(C(F)(F)F)C=C1)C1=CC=CC=C1)[C@@H]1O[C@H](C(=O)O[Si](C)(C)C)[C@@H](O)[C@H](O[Si](C)(C)C)[C@H]1O[Si](C)(C)C | 3106.8 | Semi standard non polar | 33892256 | | Fluoxetine glucuronide,4TMS,isomer #1 | CN(CCC(OC1=CC=C(C(F)(F)F)C=C1)C1=CC=CC=C1)[C@@H]1O[C@H](C(=O)O[Si](C)(C)C)[C@@H](O[Si](C)(C)C)[C@H](O[Si](C)(C)C)[C@H]1O[Si](C)(C)C | 3128.3 | Semi standard non polar | 33892256 | | Fluoxetine glucuronide,1TBDMS,isomer #1 | CN(CCC(OC1=CC=C(C(F)(F)F)C=C1)C1=CC=CC=C1)[C@@H]1O[C@H](C(=O)O)[C@@H](O[Si](C)(C)C(C)(C)C)[C@H](O)[C@H]1O | 3277.7 | Semi standard non polar | 33892256 | | Fluoxetine glucuronide,1TBDMS,isomer #2 | CN(CCC(OC1=CC=C(C(F)(F)F)C=C1)C1=CC=CC=C1)[C@@H]1O[C@H](C(=O)O)[C@@H](O)[C@H](O[Si](C)(C)C(C)(C)C)[C@H]1O | 3285.9 | Semi standard non polar | 33892256 | | Fluoxetine glucuronide,1TBDMS,isomer #3 | CN(CCC(OC1=CC=C(C(F)(F)F)C=C1)C1=CC=CC=C1)[C@@H]1O[C@H](C(=O)O)[C@@H](O)[C@H](O)[C@H]1O[Si](C)(C)C(C)(C)C | 3315.1 | Semi standard non polar | 33892256 | | Fluoxetine glucuronide,1TBDMS,isomer #4 | CN(CCC(OC1=CC=C(C(F)(F)F)C=C1)C1=CC=CC=C1)[C@@H]1O[C@H](C(=O)O[Si](C)(C)C(C)(C)C)[C@@H](O)[C@H](O)[C@H]1O | 3288.7 | Semi standard non polar | 33892256 | | Fluoxetine glucuronide,2TBDMS,isomer #1 | CN(CCC(OC1=CC=C(C(F)(F)F)C=C1)C1=CC=CC=C1)[C@@H]1O[C@H](C(=O)O[Si](C)(C)C(C)(C)C)[C@@H](O[Si](C)(C)C(C)(C)C)[C@H](O)[C@H]1O | 3517.8 | Semi standard non polar | 33892256 | | Fluoxetine glucuronide,2TBDMS,isomer #2 | CN(CCC(OC1=CC=C(C(F)(F)F)C=C1)C1=CC=CC=C1)[C@@H]1O[C@H](C(=O)O)[C@@H](O[Si](C)(C)C(C)(C)C)[C@H](O[Si](C)(C)C(C)(C)C)[C@H]1O | 3507.1 | Semi standard non polar | 33892256 | | Fluoxetine glucuronide,2TBDMS,isomer #3 | CN(CCC(OC1=CC=C(C(F)(F)F)C=C1)C1=CC=CC=C1)[C@@H]1O[C@H](C(=O)O)[C@@H](O[Si](C)(C)C(C)(C)C)[C@H](O)[C@H]1O[Si](C)(C)C(C)(C)C | 3512.0 | Semi standard non polar | 33892256 | | Fluoxetine glucuronide,2TBDMS,isomer #4 | CN(CCC(OC1=CC=C(C(F)(F)F)C=C1)C1=CC=CC=C1)[C@@H]1O[C@H](C(=O)O[Si](C)(C)C(C)(C)C)[C@@H](O)[C@H](O[Si](C)(C)C(C)(C)C)[C@H]1O | 3521.2 | Semi standard non polar | 33892256 | | Fluoxetine glucuronide,2TBDMS,isomer #5 | CN(CCC(OC1=CC=C(C(F)(F)F)C=C1)C1=CC=CC=C1)[C@@H]1O[C@H](C(=O)O)[C@@H](O)[C@H](O[Si](C)(C)C(C)(C)C)[C@H]1O[Si](C)(C)C(C)(C)C | 3511.7 | Semi standard non polar | 33892256 | | Fluoxetine glucuronide,2TBDMS,isomer #6 | CN(CCC(OC1=CC=C(C(F)(F)F)C=C1)C1=CC=CC=C1)[C@@H]1O[C@H](C(=O)O[Si](C)(C)C(C)(C)C)[C@@H](O)[C@H](O)[C@H]1O[Si](C)(C)C(C)(C)C | 3547.2 | Semi standard non polar | 33892256 | | Fluoxetine glucuronide,3TBDMS,isomer #1 | CN(CCC(OC1=CC=C(C(F)(F)F)C=C1)C1=CC=CC=C1)[C@@H]1O[C@H](C(=O)O[Si](C)(C)C(C)(C)C)[C@@H](O[Si](C)(C)C(C)(C)C)[C@H](O[Si](C)(C)C(C)(C)C)[C@H]1O | 3697.8 | Semi standard non polar | 33892256 | | Fluoxetine glucuronide,3TBDMS,isomer #2 | CN(CCC(OC1=CC=C(C(F)(F)F)C=C1)C1=CC=CC=C1)[C@@H]1O[C@H](C(=O)O[Si](C)(C)C(C)(C)C)[C@@H](O[Si](C)(C)C(C)(C)C)[C@H](O)[C@H]1O[Si](C)(C)C(C)(C)C | 3690.5 | Semi standard non polar | 33892256 | | Fluoxetine glucuronide,3TBDMS,isomer #3 | CN(CCC(OC1=CC=C(C(F)(F)F)C=C1)C1=CC=CC=C1)[C@@H]1O[C@H](C(=O)O)[C@@H](O[Si](C)(C)C(C)(C)C)[C@H](O[Si](C)(C)C(C)(C)C)[C@H]1O[Si](C)(C)C(C)(C)C | 3713.6 | Semi standard non polar | 33892256 | | Fluoxetine glucuronide,3TBDMS,isomer #4 | CN(CCC(OC1=CC=C(C(F)(F)F)C=C1)C1=CC=CC=C1)[C@@H]1O[C@H](C(=O)O[Si](C)(C)C(C)(C)C)[C@@H](O)[C@H](O[Si](C)(C)C(C)(C)C)[C@H]1O[Si](C)(C)C(C)(C)C | 3703.0 | Semi standard non polar | 33892256 |
|
|---|
| GC-MS Spectra| Spectrum Type | Description | Splash Key | Deposition Date | Source | View |
|---|
| Predicted GC-MS | Predicted GC-MS Spectrum - Fluoxetine glucuronide GC-MS (Non-derivatized) - 70eV, Positive | Not Available | 2021-10-12 | Wishart Lab | View Spectrum |
MS/MS Spectra| Spectrum Type | Description | Splash Key | Deposition Date | Source | View |
|---|
| Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Fluoxetine glucuronide 10V, Positive-QTOF | splash10-014r-0011900000-fd4d2d88c710c324bd4d | 2019-02-22 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Fluoxetine glucuronide 20V, Positive-QTOF | splash10-03fr-4396300000-d59759e140882c8ffa8c | 2019-02-22 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Fluoxetine glucuronide 40V, Positive-QTOF | splash10-01td-2793000000-75830be6fbdd756076fb | 2019-02-22 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Fluoxetine glucuronide 10V, Negative-QTOF | splash10-001i-0002900000-65cce196fc4336f715a4 | 2019-02-23 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Fluoxetine glucuronide 20V, Negative-QTOF | splash10-0zn9-0109100000-c2a7004be6945708c863 | 2019-02-23 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Fluoxetine glucuronide 40V, Negative-QTOF | splash10-08fr-6902000000-fe3ed739d84225072cd2 | 2019-02-23 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Fluoxetine glucuronide 10V, Positive-QTOF | splash10-000i-0322900000-884bb7509af784586dc6 | 2021-10-12 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Fluoxetine glucuronide 20V, Positive-QTOF | splash10-03xv-2944200000-c640d5983de23b049ff3 | 2021-10-12 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Fluoxetine glucuronide 40V, Positive-QTOF | splash10-014i-1930000000-2b3629852d249a0011f0 | 2021-10-12 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Fluoxetine glucuronide 10V, Negative-QTOF | splash10-01q9-0422900000-0f6de9d60ca6fe0211d8 | 2021-10-12 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Fluoxetine glucuronide 20V, Negative-QTOF | splash10-03di-0900000000-bd188465112d19041b74 | 2021-10-12 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Fluoxetine glucuronide 40V, Negative-QTOF | splash10-03di-0900000000-762b41102a732472c728 | 2021-10-12 | Wishart Lab | View Spectrum |
NMR Spectra| Spectrum Type | Description | Deposition Date | Source | View |
|---|
| Predicted 1D NMR | 13C NMR Spectrum (1D, 100 MHz, D2O, predicted) | 2021-09-24 | Wishart Lab | View Spectrum | | Predicted 1D NMR | 1H NMR Spectrum (1D, 100 MHz, D2O, predicted) | 2021-09-24 | Wishart Lab | View Spectrum | | Predicted 1D NMR | 13C NMR Spectrum (1D, 1000 MHz, D2O, predicted) | 2021-09-24 | Wishart Lab | View Spectrum | | Predicted 1D NMR | 1H NMR Spectrum (1D, 1000 MHz, D2O, predicted) | 2021-09-24 | Wishart Lab | View Spectrum | | Predicted 1D NMR | 13C NMR Spectrum (1D, 200 MHz, D2O, predicted) | 2021-09-24 | Wishart Lab | View Spectrum | | Predicted 1D NMR | 1H NMR Spectrum (1D, 200 MHz, D2O, predicted) | 2021-09-24 | Wishart Lab | View Spectrum | | Predicted 1D NMR | 13C NMR Spectrum (1D, 300 MHz, D2O, predicted) | 2021-09-24 | Wishart Lab | View Spectrum | | Predicted 1D NMR | 1H NMR Spectrum (1D, 300 MHz, D2O, predicted) | 2021-09-24 | Wishart Lab | View Spectrum | | Predicted 1D NMR | 13C NMR Spectrum (1D, 400 MHz, D2O, predicted) | 2021-09-24 | Wishart Lab | View Spectrum | | Predicted 1D NMR | 1H NMR Spectrum (1D, 400 MHz, D2O, predicted) | 2021-09-24 | Wishart Lab | View Spectrum | | Predicted 1D NMR | 13C NMR Spectrum (1D, 500 MHz, D2O, predicted) | 2021-09-24 | Wishart Lab | View Spectrum | | Predicted 1D NMR | 1H NMR Spectrum (1D, 500 MHz, D2O, predicted) | 2021-09-24 | Wishart Lab | View Spectrum | | Predicted 1D NMR | 13C NMR Spectrum (1D, 600 MHz, D2O, predicted) | 2021-09-24 | Wishart Lab | View Spectrum | | Predicted 1D NMR | 1H NMR Spectrum (1D, 600 MHz, D2O, predicted) | 2021-09-24 | Wishart Lab | View Spectrum | | Predicted 1D NMR | 13C NMR Spectrum (1D, 700 MHz, D2O, predicted) | 2021-09-24 | Wishart Lab | View Spectrum | | Predicted 1D NMR | 1H NMR Spectrum (1D, 700 MHz, D2O, predicted) | 2021-09-24 | Wishart Lab | View Spectrum | | Predicted 1D NMR | 13C NMR Spectrum (1D, 800 MHz, D2O, predicted) | 2021-09-24 | Wishart Lab | View Spectrum | | Predicted 1D NMR | 1H NMR Spectrum (1D, 800 MHz, D2O, predicted) | 2021-09-24 | Wishart Lab | View Spectrum | | Predicted 1D NMR | 13C NMR Spectrum (1D, 900 MHz, D2O, predicted) | 2021-09-24 | Wishart Lab | View Spectrum | | Predicted 1D NMR | 1H NMR Spectrum (1D, 900 MHz, D2O, predicted) | 2021-09-24 | Wishart Lab | View Spectrum |
|
|---|
| General References | - Ducker GS, Atreya CE, Simko JP, Hom YK, Matli MR, Benes CH, Hann B, Nakakura EK, Bergsland EK, Donner DB, Settleman J, Shokat KM, Warren RS: Incomplete inhibition of phosphorylation of 4E-BP1 as a mechanism of primary resistance to ATP-competitive mTOR inhibitors. Oncogene. 2014 Mar 20;33(12):1590-600. doi: 10.1038/onc.2013.92. Epub 2013 Apr 1. [PubMed:23542178 ]
- Xing X, Zhang L, Wen X, Wang X, Cheng X, Du H, Hu Y, Li L, Dong B, Li Z, Ji J: PP242 suppresses cell proliferation, metastasis, and angiogenesis of gastric cancer through inhibition of the PI3K/AKT/mTOR pathway. Anticancer Drugs. 2014 Nov;25(10):1129-40. doi: 10.1097/CAD.0000000000000148. [PubMed:25035961 ]
- Qin Y, Zhao X, Fang Y: PP242 synergizes with suberoylanilide hydroxamic acid to inhibit growth of ovarian cancer cells. Int J Gynecol Cancer. 2014 Oct;24(8):1373-80. doi: 10.1097/IGC.0000000000000238. [PubMed:25188886 ]
- Shi F, Yang X, Gong Y, Shi R, Yang X, Naren D, Wu J: The antileukemia roles of PP242 alone or in combination with daunorubicin in acute leukemia. Anticancer Drugs. 2015 Apr;26(4):410-21. doi: 10.1097/CAD.0000000000000200. [PubMed:25535978 ]
- Cheng L, Xia Z, Bian X, Li G, Hu J, Cao Y, Wang Q, Qian X: Combination of cetuximab and PP242 synergistically suppress the progression of wild-type KRAS colorectal carcinoma. Onco Targets Ther. 2015 Nov 2;8:3185-92. doi: 10.2147/OTT.S82453. eCollection 2015. [PubMed:26586952 ]
|
|---|